NDAORALCAPSULEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19
Clinical Trials (5)
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Started Jan 2019
103 enrolled
ALK-positive Advanced NSCLC
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
Started Jun 2018
27 enrolled
MelanomaUnresectable MelanomaAdvanced Melanoma
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Started Sep 2017
9 enrolled
Non-small Cell Lung Cancer
Ceritinib Rare Indications Study in ALK+ Tumors
Started May 2016
22 enrolled
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
Started Feb 2016
10 enrolled
GlioblastomaBrain Metastases
Loss of Exclusivity
LOE Date
Feb 2, 2032
71 months away
Patent Expiry
Feb 2, 2032
External Resources